Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
暂无分享,去创建一个
P. Hari | M. Sorror | M. Maris | R. Storb | B. Sandmaier | D. Maloney | B. Storer | M. Mielcarek | M. Boyer | R. Maziarz | G. McDonald | Paul J. Martin | W. Hogan | A. Langston | W. Bethge | B. Bruno | H. Deeg | J. Gutman | A. Yeager | J. Shizuru | G. Georges | M. Flowers | J. Asch | B. Scott | K. Hübel | Georg-Nikolaus Franke | A. Woolfrey | T. Chauncey | B. Gyurkocza | F. Sahebi | E. Agura | Noa Granot | G. Olesen | S. L. Petersen | J. Cooper | P. Martin | G. Franke | Jason P. Cooper
[1] M. Maris,et al. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. , 2019, The Lancet. Haematology.
[2] R. Storb,et al. Second allogeneic hematopoietic cell transplantation for relapse after first allografts , 2019, Leukemia & lymphoma.
[3] R. Storb,et al. Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms , 2019, Haematologica.
[4] G. Mufti,et al. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis , 2018, Journal of internal medicine.
[5] P. Hari,et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. , 2017, Blood.
[6] I. Flinn,et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.
[7] I. Flinn,et al. Enasidenib in mutant IDH 2 relapsed or refractory acute myeloid leukemia , 2017 .
[8] J. Byrd,et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. , 2016, Blood.
[9] A. Letai,et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. , 2016, Cancer discovery.
[10] M. Liedtke,et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.
[11] J. Little,et al. Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant , 2016, Bone Marrow Transplantation.
[12] P. Armand,et al. The addition of sirolimus to the graft‐versus‐host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial , 2016, British journal of haematology.
[13] F. Hodi,et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. , 2016, The New England journal of medicine.
[14] P. Hari,et al. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation , 2014, Haematologica.
[15] M. Cazzola,et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Stephanie J. Lee,et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] H. Deeg,et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] K. Beiske,et al. [Invasive fungal infection]. , 2012, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[19] K. Götze,et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses , 2012, Leukemia.
[20] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[21] J. Beyene,et al. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials , 2012, British Journal of Cancer.
[22] A. Kiani,et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial , 2011, Leukemia.
[23] N. Geller,et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. , 2011, The Lancet. Oncology.
[24] Michael Boeckh,et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.
[25] G. Morgan,et al. An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality , 2009, Bone Marrow Transplantation.
[26] R. Storb,et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. , 2009, Blood.
[27] B. Storer,et al. Adjusted estimates for time-to-event endpoints , 2008, Lifetime data analysis.
[28] Patricia Muñoz,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] M. Boeckh,et al. Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. , 2008, Blood.
[30] L. Leibovici,et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Maris,et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2007, Blood.
[32] G. Kobbe,et al. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. , 2007, Leukemia research.
[33] H. Döhner,et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] M. Sorror,et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.
[35] L. Leibovici,et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. , 2005, The Cochrane database of systematic reviews.
[36] M. Turner,et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[37] G. Schoch,et al. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. , 2005, Kidney international.
[38] T. Stevens-Ayers,et al. Optimization of Quantitative Detection of Cytomegalovirus DNA in Plasma by Real-Time PCR , 2004, Journal of Clinical Microbiology.
[39] M. Remberger,et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. , 2002, Blood.
[40] P. Griffiths,et al. Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] H. Einsele,et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. , 2002, Blood.
[42] T. Hibi,et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.
[43] R. Tedder,et al. Extended routine polymerase chain reaction surveillance and pre‐emptive antiviral therapy for cytomegalovirus after allogeneic transplantation , 2000, British journal of haematology.
[44] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[45] P. Ljungman,et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. , 1998, Transplantation.
[46] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[47] K. Sullivan,et al. Ursodeoxycholic Acid Treatment of Refractory Chronic Graft-versus-Host Disease of the Liver , 1992, Annals of Internal Medicine.